Advanced Parkinson’s Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis [PDF]
, 2021 Mihaela Simu +6 more
openalex +1 more source
New‐Onset Psychosis in a Person with Parkinson's Disease after “Horny Goat Weed” Use
Movement Disorders Clinical Practice, EarlyView.
Juan R. Deliz +3 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background Many patients with Parkinson's disease (PD) have motor impairments despite dopaminergic therapy. Low‐intensity transcranial ultrasound stimulation (TUS) is a non‐invasive neuromodulation method with high spatial precision. The effects of motor cortex (M1) and internal globus pallidus (GPi) TUS on PD motor signs and cortical ...
Yi‐Ying Lin +8 more
wiley +1 more source
Brain catecholamine depletion and motor impairment in a Th knock-in mouse with type B tyrosine hydroxylase deficiency [PDF]
, 2015 Tyrosine hydroxylase catalyses the hydroxylation of L-tyrosine to l-DOPA, the rate- limiting step in the synthesis of catecholamines. Mutations in the TH gene encoding tyrosine hydroxylase are associated with the autosomal recessive disorder tyrosine ...
Allegri, Gabriella +17 more
core +3 more sources
Movement Disorders, EarlyView.Abstract Objective Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor ...
Olivier Rascol +106 more
wiley +1 more source
Parkinson’s Disease Managing Reversible Neurodegeneration [Retraction]
Neuropsychiatric Disease and Treatment, 2020 Hinz M, Stein A, Cole T, McDougall B, Westaway M. Neuropsychiatr Dis Treat. 2016;12:763–775. The Editor-in-chief and Publisher of Neuropsychiatric Disease and Treatment wish to retract the published article.
Hinz M +4 more
doaj
Advanced Parkinson's disease: Clinical characteristics and treatment. Part II
Neurología (English Edition), 2013 Introduction: Many patients who have had Parkinson's disease (PD) for several years will present severe motor fluctuations and dyskinesias which require more aggressive therapies.
J. Kulisevsky +15 more
doaj +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Progress Notes : a report from the Parkinson's Disease Center at Boston University Medical Center [PDF]
, 1991 News and updates from the Boston University Medical Center Parkinson's Disease ...
Parkinson's Disease Center at Boston University Medical Center
core +3 more sources
Dopa-responsive dystonia and hyperprolactinaemia : a novel association in two sisters [PDF]
, 2007 Dopa-Responsive Dystonia (DRD) is a rare hereditary condition of childhood-onset dystonia which responds dramatically to treatment with levodopa. It was first described in 1971 as a "hereditary progressive basal ganglia disease with marked diurnal ...
Cachia, Mario J., Galea, Janabel
core